Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Key Takeaways:

• Teva and Sanofi collaborated on duvakitug for inflammatory bowel diseases
• Phase 2b data showed durable efficacy in both ulcerative colitis and Crohn’s disease
• Teva will hold an investor call and webcast on February 17, 2026
• The original news was published on February 17, 2026, via Globe Newswire

Duvakitug’s Phase 2b Results

Teva and Sanofi have announced encouraging findings from a phase 2b clinical trial investigating duvakitug, a therapy designed to address two challenging inflammatory bowel diseases: ulcerative colitis and Crohn’s disease. According to the companies, these results demonstrate clinically meaningful and durable efficacy, suggesting a promising treatment option for patients living with these conditions.

Collaboration Between Teva and Sanofi

Both Teva and Sanofi are internationally recognized for their pharmaceutical work. By combining resources and expertise, they aim to advance potential new therapies and improve outcomes for patients who face limited options for managing their chronic digestive disorders.

Key Efficacy Data

While detailed figures from the trial were not included in the public release, the announcement emphasizes that duvakitug showed a sustained therapeutic effect for individuals in the study. Teva and Sanofi anticipate that further analyses of these results will help clarify the drug’s potential for a broader patient population.

Next Steps and Investor Call

To share deeper insights and data interpretation, Teva will host an investor call and live webcast on February 17, 2026, at 8:00 a.m. ET. Interested parties, including stakeholders and members of the medical community, are expected to learn more about duvakitug’s trial performance and future research directions. Additional information can be found through the link provided in the original Globe Newswire announcement.